A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients

A small but not insignificant number of patients experience a prolonged survival after treatment of metastatic soft tissue sarcoma. This must be weighed against the majority of the patients who benefit little from the therapy, but nevertheless experience its side-effects. It would therefore be of ut...

Descripción completa

Detalles Bibliográficos
Autores principales: Huuhtanen, R L, Wiklund, T A, Blomqvist, C P, Böhling, T O, Virolainen, M J, Tribukait, B, Andersson, L C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362954/
https://www.ncbi.nlm.nih.gov/pubmed/10576659
http://dx.doi.org/10.1038/sj.bjc.6690801
_version_ 1782153582777204736
author Huuhtanen, R L
Wiklund, T A
Blomqvist, C P
Böhling, T O
Virolainen, M J
Tribukait, B
Andersson, L C
author_facet Huuhtanen, R L
Wiklund, T A
Blomqvist, C P
Böhling, T O
Virolainen, M J
Tribukait, B
Andersson, L C
author_sort Huuhtanen, R L
collection PubMed
description A small but not insignificant number of patients experience a prolonged survival after treatment of metastatic soft tissue sarcoma. This must be weighed against the majority of the patients who benefit little from the therapy, but nevertheless experience its side-effects. It would therefore be of utmost importance to be able to screen for those patients who respond to the treatment. Since proliferating cells are more sensitive to chemotherapy than non-proliferative cells, we measured the proliferation rate of the primary tumour of 55 soft tissue sarcoma patients with locally advanced or metastatic disease by determining the flow cytometric S phase fraction and immunohistochemical Ki-67 and cyclin A scores. S phase fraction or Ki-67 score did not predict chemotherapy response or progression-free survival. A high cyclin A score, however, correlated with a better chemotherapy response (P = 0.02) and longer progression-free survival time (P = 0.04). Our results suggest that a high cyclin A score predicts chemotherapy sensitivity. © 1999 Cancer Research Campaign
format Text
id pubmed-2362954
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23629542009-09-10 A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients Huuhtanen, R L Wiklund, T A Blomqvist, C P Böhling, T O Virolainen, M J Tribukait, B Andersson, L C Br J Cancer Regular Article A small but not insignificant number of patients experience a prolonged survival after treatment of metastatic soft tissue sarcoma. This must be weighed against the majority of the patients who benefit little from the therapy, but nevertheless experience its side-effects. It would therefore be of utmost importance to be able to screen for those patients who respond to the treatment. Since proliferating cells are more sensitive to chemotherapy than non-proliferative cells, we measured the proliferation rate of the primary tumour of 55 soft tissue sarcoma patients with locally advanced or metastatic disease by determining the flow cytometric S phase fraction and immunohistochemical Ki-67 and cyclin A scores. S phase fraction or Ki-67 score did not predict chemotherapy response or progression-free survival. A high cyclin A score, however, correlated with a better chemotherapy response (P = 0.02) and longer progression-free survival time (P = 0.04). Our results suggest that a high cyclin A score predicts chemotherapy sensitivity. © 1999 Cancer Research Campaign Nature Publishing Group 1999-11 /pmc/articles/PMC2362954/ /pubmed/10576659 http://dx.doi.org/10.1038/sj.bjc.6690801 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Huuhtanen, R L
Wiklund, T A
Blomqvist, C P
Böhling, T O
Virolainen, M J
Tribukait, B
Andersson, L C
A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients
title A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients
title_full A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients
title_fullStr A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients
title_full_unstemmed A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients
title_short A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients
title_sort high proliferation rate measured by cyclin a predicts a favourable chemotherapy response in soft tissue sarcoma patients
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362954/
https://www.ncbi.nlm.nih.gov/pubmed/10576659
http://dx.doi.org/10.1038/sj.bjc.6690801
work_keys_str_mv AT huuhtanenrl ahighproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients
AT wiklundta ahighproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients
AT blomqvistcp ahighproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients
AT bohlingto ahighproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients
AT virolainenmj ahighproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients
AT tribukaitb ahighproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients
AT anderssonlc ahighproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients
AT huuhtanenrl highproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients
AT wiklundta highproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients
AT blomqvistcp highproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients
AT bohlingto highproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients
AT virolainenmj highproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients
AT tribukaitb highproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients
AT anderssonlc highproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients